Autopsy report · NCT01901328

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

“Sponsor decision due to lack of enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 10 months before it stopped.
• 49 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Sponsor type

Industry

Conditions

Opioid-Induced Constipation

Interventions

CB-5945; Placebo

Participants

49

Trials that died the same way

• A Clinical Investigation Evaluating Peristeen® Performance
  “Lack of enrollment - Sponsor decision” (95% match in meaning)
• Digital Remote Home Monitoring for Heart Failure
  “Due to sponsor request for poor enrollment” (86% match in meaning)
• Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
  “Closed by sponsor, lack of enrollment.” (83% match in meaning)
• CorPath GRX STEMI Study
  “Low enrollment and sponsor business decision” (81% match in meaning)
• Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
  “due to lack of enrollment and changes to the sponsor development portfolio” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.